DPP-4 inhibition by Linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlip3/ASC

Project: Other project

StatusActive
Effective start/end date4/13/1512/1/19

Funding

  • Boehringer Ingelheim Pharmaceuticals: $150,428.62